

Milbeguard Duo 25 mg / 250 mg chewable tablets for large dogs

Authorised

- Milbemycin oxime
- Praziquantel

Product identification

Medicine name:

Milbeguard Duo 25 mg / 250 mg chewable tablets for large dogs

Active substance:

Milbemycin oxime

Praziquantel

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Milbemycin oxime

25.00 milligram(s) / 1.00 Tablet

Praziquantel

250.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Lithuania

Package description:

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 1 blister of 2 tablets (2 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 2 blisters of 2 tablets (4 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 5 blisters of 2 tablets (10 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 12 blisters of 2 tablets (24 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 24 blisters of 2 tablets (48 tablets).

Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 50 blisters of 2 tablets (100 tablets).

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application – change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)

Marketing authorisation holder:

Ceva Sante Animale

Marketing authorisation date:

16/11/2023

Manufacturing sites for batch release:

Ceva Sante Animale

Responsible authority:

State Food And Veterinary Service

Authorisation number:

LT/2/23/2781/001-006

Date of authorisation status change:

16/11/2023

Reference member state:

Ireland

Procedure number:

IE/V/0780/003

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Germany Greece Hungary Italy Latvia Lithuania Luxembourg
Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet